[go: up one dir, main page]
Wikipedia

Telogen effluvium

Telogen effluvium is a scalp disorder characterized by the thinning or shedding of hair resulting from the early entry of hair in the telogen phase (the resting phase of the hair follicle).[1][2][3] It is in this phase that telogen hairs begin to shed at an increased rate, where normally the approximate rate of hair loss (having no effect on one's appearance) is 125 hairs per day.[4]

Telogen effluvium
An Afghan child displaying hair loss due to severe malnutrition
SpecialtyDermatology Edit this on Wikidata

There are 5 potential alterations in the hair cycle that could lead to this shedding: immediate anagen release, delayed anagen release, short anagen syndrome, immediate telogen release, and delayed telogen release.[4][5]

  • Immediate anagen release occurs when follicles leave anagen and are stimulated to enter telogen prematurely. The effects become visible 2–3 months later with increased telogen effluvium.
  • Delayed anagen release, most commonly associated with pregnancy, involves the prolongation of anagen under the effect of pregnancy hormones, resulting in delayed but synchronous and heavy postpartum hair shedding.
  • Short anagen syndrome is characterized by an idiopathic and persistent telogen hair shedding, as well as the inability to grow hair long. This is a result of the shortening of the duration of anagen, meaning a greater number of telogen hairs at any given time, and is responsible for the majority of chronic TE cases.
  • Immediate telogen release generally occurs with drug-induced shortening of telogen leading to the premature reentrance of follicles to anagen, which causes a massive release of club (telogen) hairs. Drugs such as minoxidil can precipitate immediate telogen release.
  • Delayed telogen release involves a prolonged telogen phase followed by a delayed transition to anagen. This occurs in animals with synchronous hair cycles that shed their hair or winter coats seasonally. This is also sometimes responsible for seasonal hair loss in humans.[4][5][6]

Emotional or physiological stress may result in an alteration of the normal hair cycle and cause the disorder, with potential causes including eating disorders, crash diets, pregnancy and childbirth, chronic illness, major surgery, anemia, severe emotional disorders, hypothyroidism, and drugs.[1][7]

Diagnostic tests, which may be performed to verify the diagnosis, include a trichogram, trichoscopy[8] and biopsy.[7] Effluvium can present with similar appearance to alopecia totalis, with further distinction by clinical course, microscopic examination of plucked follicles, or biopsy of the scalp.[9] Histology would show telogen hair follicles in the dermis with minimal inflammation in effluvium, and dense peribulbar lymphocytic infiltrate in alopecia totalis.[10]

Vitamin D levels may also play a role in the normal hair cycle.[11]

Many new cosmetic treatments have been reported, including Stemoxydine, Nioxin, minoxidil, and a leave-on technology combination: caffeine, niacinamide, panthenol, dimethicone, and an acrylate polymer (CNPDA). This treatment has shown to increase the diameter of existing, individual scalp hair fibres by 2–5 μm, yielding a significant increase of approximately 10% in the cross-sectional area of each hair. Additionally, CNPDA-thickened hairs also demonstrate altered mechanical properties of thicker fibres; increased suppleness/pliability, and increased ability to withstand force without breaking.[12]

See also

edit

References

edit
  1. ^ a b Marks, James G; Miller, Jeffery (2006). Lookingbill and Marks' Principles of Dermatology (4th ed.). Elsevier Inc. Page 263. ISBN 1-4160-3185-5.
  2. ^ James, William; Berger, Timothy; Elston, Dirk (2005). Andrews' Diseases of the Skin: Clinical Dermatology. (10th ed.). Saunders. ISBN 0-7216-2921-0.
  3. ^ Asghar, Fahham; Shamim, Nazia; Farooque, Umar; Sheikh, Haris; Aqeel, Ramsha (2020). "Telogen Effluvium: A Review of the Literature". Cureus. 12 (5): e8320. doi:10.7759/cureus.8320. PMC 7320655. PMID 32607303.
  4. ^ a b c Khan Mohammad Beigi, Pooya (2018). "Introduction". In Khan Mohammad Beigi, Pooya (ed.). Alopecia Areata: A Clinician's Guide. Springer International Publishing. pp. 3–5. doi:10.1007/978-3-319-72134-7_1. ISBN 9783319721347.
  5. ^ a b Liyanage, Deepa; Sinclair, Rodney (2016-03-25). "Telogen Effluvium". Cosmetics. 3 (2): 13. doi:10.3390/cosmetics3020013. ISSN 2079-9284.
  6. ^ Grover, Chander; Khurana, Ananta (2013). "Telogen effluvium". Indian Journal of Dermatology, Venereology and Leprology. 79 (5): 591–603. doi:10.4103/0378-6323.116731. ISSN 0378-6323. PMID 23974577.
  7. ^ a b Freedberg, et al. (2003). Fitzpatrick's Dermatology in General Medicine. (6th ed.). McGraw-Hill. ISBN 0-07-138076-0.
  8. ^ Rudnicka L, Olszewska M, Rakowska A, Kowalska-Oledzka E, Slowinska M (2008). "Trichoscopy: a new method for diagnosing hair loss". J Drugs Dermatol. 7 (7): 651–654. PMID 18664157.
  9. ^ Werner, B.; Mulinari-Brenner, F. (2012). "Clinical and histological challenge in the differential diagnosis of diffuse alopecia: Female androgenetic alopecia, telogen effluvium and alopecia areata – part II". Anais Brasileiros de Dermatologia. 87 (6): 884–890. doi:10.1590/S0365-05962012000600010. PMC 3699921. PMID 23197208.
  10. ^ Alkhalifah, A. (2012). "Alopecia Areata Update". Dermatologic Clinics. 31 (1): 93–108. doi:10.1016/j.det.2012.08.010. PMID 23159179.
  11. ^ Amor KT, Rashid RM, Mirmirani P (2010). "Does D matter? The role of vitamin D in hair disorders and hair follicle cycling". Dermatol. Online J. 16 (2): 3. doi:10.5070/D38S34P6B7. PMID 20178699.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  12. ^ Davis, M.G.; Thomas, J.H.; van de Velde, S.; Boissy, Y.; Dawson, T.L.; Iveson, R.; Sutton, K. (December 2011). "A novel cosmetic approach to treat thinning hair". British Journal of Dermatology. 165: 24–30. doi:10.1111/j.1365-2133.2011.10633.x. ISSN 0007-0963. PMID 22171682. S2CID 21918537.
edit
Retrieved from "https://en.wikipedia.org/w/index.php?title=Telogen_effluvium&oldid=1259552511"